Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer
Join Toni Choueiri, MD, and Bradley McGregor, MD from Dana-Farber Cancer Institute as they present their multidisciplinary expertise on a range of cases pertaining to kidney cancer.
Target Audience
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Identify key patient and clinical factors that influence first-line treatment selection for patients with advanced renal cell carcinoma (RCC).
- Design optimal treatment plan after disease progression for patients with advanced RCC.
- Learn the adverse events associated with the new therapies available for advanced RCC and strategies to manage them
Toni Choueiri, MD
Dana-Farber Cancer Institute
Bradley McGregor, MD
Dana-Farber Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below disclose the following relevant financial relationships:
Toni Choueiri, MD
Bristol-Myers Squibb Company – Consulting Fees; Honoraria; Scientific Advisor; Grant/Research Support
Exelixis, Inc. – Consulting Fees; Honoraria; Scientific Advisor; Grant/Research Support
Merck & Co., Inc. - Consulting Fees; Honoraria; Scientific Advisor; Grant/Research Support
Pfizer – Consulting Fees; Honoraria; Scientific Advisor
Bradley McGregor, MD
Astellas – Honoraria
AstraZeneca – Scientific Advisor
Decibel – Scientific Advisory
Exelixis – Honoraria; Advisory Board
Genentech – Honoraria
Nektar – Scientific Advisor
Pfizer – Consulting Fees
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017)
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Katie Pierce
Boston Scientific Corporation – Equity Interest/Stock Options
Pfizer Inc. – Equity Interest/Stock Options
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Rashmi Kumar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.75 contact hours.
Pharmacists
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. UAN: 0836-0000-18-091-H01-P
Available Credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.69 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing